Company intelligence / Profile preview

Renovia

Boston, Massachusetts, United Statesrenovia.com ↗

Ownership: Private
Development stage: Commercial

Overview

Renovia’s leva Pelvic Health System has received FDA clearance as a first-line treatment for both urinary and chronic fecal incontinence in women. Clinical studies have shown that the digital system outperforms unsupervised Kegel exercises for urinary incontinence. The device provides real-time feedback via a vaginal motion sensor paired with a smartphone app and enables discreet at-home therapy. The system has also received Breakthrough Device Designation from the FDA for chronic fecal incontinence.

Therapeutic areas: GastroenterologyWomen's Health
Modalities: DeviceDigital Therapeutic
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Leva Pelvic Health System

Commercial

Indications: urinary incontinence, fecal incontinence

Beyond the preview

Go deeper on Renovia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renovia.

Explore the full profile